肿瘤预防与治疗2026，Vol.39Issue(2)：147-152,6.DOI:10.3969/j.issn.1674-0904.2026.02.009
吡非尼酮在肿瘤治疗中的研究进展
Research Progress of Pirfenidone in Cancer Treatment
摘要
Abstract
Pirfenidone,an FDA-approved drug for idiopathic pulmonary fibrosis,has demonstrated potential in cancer therapy due to its anti-fibrotic,antioxidant,and anti-inflammatory properties.Research has shown that pirfenidone directly inhibits tumor cell proliferation and metastasis through multiple mechanisms,including the suppression of key signaling path-ways(e.g.,TGF-β/SMAD),cell cycle regulation,apoptosis induction,and the inhibition of epithelial-mesenchymal tran-sition.In addition,pirfenidone enhances anti-tumor immune responses indirectly by remodeling the tumor microenvironment,primarily by inhibiting extracellular matrix deposition;modulating cance-associated fibroblast function;and promoting im-mune cell infiltration and polarization.Furthermore,combining pirfenidone with chemotherapy,targeted therapy,or immune checkpoint inhibitors exhibits synergistic effects,presenting a promising strategy to overcome tumor drug resistance and im-mune suppression.Therefore,further in-depth research and clinical trials are expected to clarify the broad application value of pirfenidone in cancer treatment,providing more therapeutic options for cancer patients.关键词
吡非尼酮/肿瘤/免疫治疗/肿瘤微环境/TGF-β信号通路Key words
Pirfenidone/Tumor/Immunotherapy/Tumor microenvironment/TGF-β signaling pathway分类
医药卫生引用本文复制引用
孙培旺,郭园园..吡非尼酮在肿瘤治疗中的研究进展[J].肿瘤预防与治疗,2026,39(2):147-152,6.基金项目
This study was supported by grants from Health Commission of Anhui Province(No.AHWJ2023A10096)and Education Department of Anhui Province(No.2024AH040191). 安徽省卫健委科研项目重点项目(编号:AHWJ2023A10096) （No.AHWJ2023A10096）
安徽省高校科研项目重大项目(编号:2024AH040191) （编号:2024AH040191）
